Capital raising & IPOs

We offer a comprehensive service covering all aspects of IPOs. We advise on capital raising, legal liabilities and obligations, managing the due diligence process, and negotiation of underwriting or IPO management agreements – and more than this, our extensive knowledge in this field allows us to add value at a strategic level. Our advice on risk management, timings and even logistics, as well as our long-standing relationships at ASIC and ASX, have proven invaluable to our clients and earned us the position of genuine trusted advisor.

Our IPO experience includes acting for Regeneus, Simavita, QRxPharma, China Century Capital and CAP-XX.


Regeneus: As the first Australian biotechnology float on the Australian Securities Exchange since 2011, our support of Regeneus’ listing was integral to their success in raising the funds and securing such a high value on their initial listing. Having worked with the firm since its inception in 2007, our sound understanding of their ethos and objectives, combined with our extensive industry experience, ensured a successful and smooth collaboration with all parties delivering the IPO.

Scheme of arrangement and fundraising: DibbsBarker acted for Simavita Holdings Limited on a reverse takeover and a contemporaneous fundraising where they raised $14 million from new and existing shareholders. We supported in navigating a complicated deal structure and engaging with a large number of stakeholders including ASIC, the court, shareholders and international counterparts. These highly complex transactions were transformational for our client, positioning the merged group for listing on the Toronto Stock Exchange Ventures Market, and then the ASX. As part of this process we devised a simple one-page diagram to show how the elements of the restructure fitted into the overall timeline.

Extending rights issues outside Australia: We acted for ASX listed speciality pharmaceutical company QRxPharma on its $50 million IPO, as well as its $21.6 million fully underwritten capital raising through institutional placement and renounceable rights issue. We also advised them on a further $20 million institutional placement and share purchase plan. Working closely with US counsel to negotiate the SEC and securities laws requirements in the US, we were able to ensure the rights issue was extended to US shareholders – one of the few instances of this occurring in Australian business.

Senior Associate
T +61 2 8233 9551
What our clients say

“DibbsBarker have been a great partner for us because of their good understanding of the issues faced by an emerging biotech company like Regeneus going through an IPO process. This comes from having the right people with the right experience in a firm with a long-term interest in the healthcare and biotechnology sector.”

John Martin, Executive Chairman, Regeneus

Recent News and Publications
03 Oct 2017
In our Safe Harbour Wheelhouse publication series we will consider how the new laws are likely to play out and impact key stakeholders once companies begin relying on the new provisions in months and years to come. In this first update, we look at some of the issues that directors and unsecured creditors will need to consider given the Corporations Act’s silence about whether or not a restructure plan should be disclosed to creditors.
29 Sep 2017
After months of anticipation, speculation and some controversy, the Turnbull government’s crowd-sourced funding (CSF) regime for unlisted public companies came into effect today, 29 September 2017.
22 Sep 2017
What do investors consider most closely when evaluating an opportunity to invest in an initial public offering (IPO)? Do institutional and retail investors place different weight on different sources of information? How well do retail investors really understand prospectuses?